Preventing Hypertension Through Lifestyle Modification: An Evidence-Based Scoping Review of Behavioral Risk Factors and Intervention Targets

lists of all included systematic reviews and meta-analyses were hand-searched for additional eligible studies. Major guideline documents from the WHO (2023), ESC (2024), ISH/WHL (2024), and AHA/ACC (2025) were retrieved directly from official publisher websites. Study Selection All search results were exported to Rayyan (a web-based systematic review management tool) for deduplication and blinded screening. Two independent reviewers (the first author and a trained research assistant) screened titles and abstracts against the eligibility criteria. Full texts of all potentially eligible records were retrieved and independently assessed. Discrepancies at either stage were resolved through discussion and consensus. A PRISMA-ScR flow diagram documenting the number of records identified, screened, excluded (with reasons at full-text stage), and included is presented in Figure 1 [to be inserted at final submission]. Data Extraction and Synthesis A standardized data extraction form was developed and piloted on five included studies prior to full extraction. For each included source, the following data were recorded: author(s) and year; country or setting; study design; population characteristics; risk factors or interventions examined; blood pressure outcomes; and principal findings relevant to the review questions. Given the scoping nature of the review, formal risk-of-bias appraisal was not conducted; however, study design hierarchy was considered in the narrative synthesis, with meta-analyses and RCTs given greater weight for effectiveness estimates. Data were synthesized narratively and organized thematically by: (i) behavioral risk factor domains and (ii) lifestyle intervention type. Results The searches across five databases yielded 1,847 unique records after deduplication. Following title and abstract screening, 312 full-text articles were assessed for eligibility, of which 47 sources met the inclusion criteria and were incorporated into the final synthesis. Overview of Included Evidence Included sources comprised 18 systematic reviews and meta-analyses, 12 RCTs or controlled trials, 8 prospective cohort studies, 5 major international clinical guidelines (WHO 2023, ESC 2024, ISH/WHL 2024, AHA/ACC 2025, WHO EMRO 2025), and 4 cross-sectional or population-based studies. Studies were conducted across 24 countries, with representation from Africa (including Nigeria), Asia, Europe, and North America. Sources published between 2020 and 2025 constituted 64% of the included evidence base, reflecting the recency of the synthesis. Behavioral Risk Factors for Hypertension 2.1 Dietary Patterns and Sodium Intake High sodium intake is among the most thoroughly documented dietary drivers of hypertension. He et al. (2020) demonstrated that each additional 2.5 g/day increase in sodium intake is associated with a 1.7 mmHg rise in SBP [9]. Global mean sodium intake is estimated at approximately 10.4 g/day—more than five times the WHO-recommended maximum of 2 g/day [10]. The 2024 ISH position paper further established population-level dietary targets: sodium below 2 g/day, potassium intake ≥3.5 g/day, and adoption of dietary patterns consistent with the DASH or Mediterranean diet [6]. Beyond sodium, the growing global prevalence of ultra-processed food consumption—driven by urbanization and food system transitions in LMICs—introduces excess sodium, saturated fat, added sugars, and low dietary fiber, all of which independently elevate blood pressure and cardiovascular risk [11]. Conversely, plant-rich dietary patterns high in fruits, vegetables, whole grains, legumes, and low-fat dairy are associated with meaningfully lower blood pressure and reduced hypertension incidence [12]. 2.2 Physical Inactivity Physical inactivity is a major independent risk factor for hypertension. Huai et al. (2013) reported that physically inactive adults had up to 35% higher odds of developing hypertension compared to regularly active peers [13]. The mechanisms are multiple and interacting: physical activity improves arterial compliance, reduces peripheral vascular resistance, attenuates sympathetic nervous system activation, and promotes favorable body composition changes. A landmark 2023 large-scale network meta-analysis by Edwards et al., incorporating 270 RCTs and 15,827 participants, confirmed that all major exercise modalities—aerobic, resistance, combined, high-intensity interval, and isometric—significantly reduce resting blood pressure [14]. Isometric exercise demonstrated the greatest SBP effect (−8.24 mmHg), followed by combined aerobic and resistance training (−6.04 mmHg), aerobic training alone (−4.49 mmHg), and dynamic resistance training (−4.55 mmHg) [14]. 2.3 Overweight and Obesity Excess adiposity contributes to hypertension through activation of the renin-angiotensin- aldosterone system , sympathetic nervous system overactivation, sodium and water retention, and chronic systemic inflammation [15]. The 2025 AHA/ACC guidelines quantify approximately 1 mmHg SBP reduction per kilogram of weight lost [16]. Abdominal obesity, measured by waist circumference or waist-to-hip ratio, is an independent predictor of hypertension risk beyond overall body mass index , reinforcing the importance of body composition-targeted interventions. 2.4 Tobacco Use Tobacco smoking acutely and chronically elevates blood pressure through catecholamine release, sympathetic stimulation, and endothelial dysfunction, and accelerates arterial stiffness and atherosclerosis over time [17]. Secondhand smoke exposure is independently associated with elevated blood pressure and increased cardiovascular risk in non-smokers [17]. Blood pressure improvements are detectable within weeks of smoking cessation, and former smokers progressively approach the cardiovascular risk profile of never-smokers [18]. 2.5 Harmful Alcohol Consumption Alcohol exerts a dose-dependent effect on blood pressure. A 2024 systematic review and dose- response meta-analysis by Cecchini et al. confirmed that hypertension risk increases with any amount of alcohol consumed by men and with more than two standard drinks per day in women [19]. For heavy drinkers (≥6 drinks/day), reducing intake is associated with SBP reductions of up to −5.5 mmHg and DBP reductions of −4.0 mmHg [6]. 2.6 Psychosocial Stress Chronic psychosocial stress activates the hypothalamic-pituitary-adrenal axis and sympathetic nervous system, elevating circulating catecholamines and cortisol, which produce sustained vasoconstriction and sodium retention contributing to elevated blood pressure [20]. Prospective evidence links work-related stress, socioeconomic adversity, social isolation, and post-traumatic stress disorder to hypertension incidence [20]. Stress also exerts compounding indirect effects by promoting poor dietary choices, increased alcohol consumption, tobacco use, and physical inactivity. 2.7 Sleep Disruption Both insufficient sleep duration (<6 hours/night) and poor sleep quality are associated with dysregulated blood pressure circadian rhythms, heightened sympathetic nervous system tone, and increased hypertension risk [21]. Obstructive sleep apnea , increasingly prevalent in the context of rising global obesity rates, is a major secondary cause of resistant hypertension and an independent cardiovascular risk factor warranting clinical assessment [21]. Evidence-Based Lifestyle Interventions 3.1 The DASH Dietary Pattern The Dietary Approaches to Stop Hypertension diet—emphasizing high intakes of fruits, vegetables, whole grains, legumes, and low-fat dairy while restricting saturated fat, red meat, sodium, and added sugars—is the most thoroughly studied dietary intervention for blood pressure management. The original DASH trial demonstrated SBP reductions of 5.5 mmHg in normotensive individuals and 11.4 mmHg in hypertensive participants compared to a control diet [22]. The DASH-Sodium trial subsequently established that combining DASH with sodium restriction produces additive reductions, achieving up to 8.9 mmHg SBP reduction against a high-sodium control [23]. More recent evidence substantially reinforces these findings. Filippou et al. (2020) systematically reviewed 30 RCTs (n = 5,545) and confirmed significant SBP and DBP reductions with DASH in both normotensive and hypertensive populations [12]. A 2023 review by Onwuzo et al.—conducted at Nigerian institutions and therefore directly relevant to the LMIC context addressed by this review—synthesized 17 RCTs (n = 2,561) and reported mean reductions of 6.74 mmHg SBP and 3.54 mmHg DBP, with greater effects observed at higher baseline blood pressure levels [24]. A 2024–2025 meta-analysis in Clinical Hypertension further confirmed that consistent DASH adherence reduces both SBP and DBP as well as total cholesterol and LDL levels [25]. Current AHA/ACC guidance quantifies DASH adherence as capable of reducing SBP by up to 13 mmHg [16]. 3.2 Sodium Restriction A Cochrane review by Aburto et al. (2013) established that a modest reduction in dietary sodium of approximately 4.4 g/day produces mean SBP reductions of 4.18 mmHg in hypertensive adults and 2.77 mmHg in normotensive individuals [26]. The 2024 ISH position paper endorses a population-level sodium target below 2 g/day and notes that the combination of DASH and sodium restriction produces the largest dietary blood pressure effects observed in clinical trials [6]. Achieving population-level sodium reduction requires multi-level action: individual dietary counseling must be complemented by food industry reformulation, front-of-pack labeling, and fiscal policies [10]. 3.3 Exercise and Physical Activity The 2023 network meta-analysis by Edwards et al. (270 RCTs, 15,827 participants) remains the most comprehensive exercise and blood pressure dataset to date, confirming that all exercise training modalities produce significant resting blood pressure reductions, with isometric training showing the greatest effect on SBP [14]. A complementary 2023 dose-response meta-analysis by Jabbarzadeh Ganjeh et al. characterized aerobic exercise dose effects specifically in hypertensive patients [27]. Critically, a 2024 meta-analysis of 60 RCTs from 18 LMICs found that physical activity interventions reduced SBP by a weighted mean of 7.70 mmHg (95% CI: −9.50 to −5.91) in resource-constrained settings [28]—affirming the feasibility and effectiveness of exercise- based interventions across diverse and lower-resource contexts. 3.4 Weight Management A meta-analysis by Neter et al. (2003) established that each kilogram of weight lost yields approximately 1 mmHg SBP reduction [29]. The Look AHEAD trial demonstrated sustained blood pressure reductions maintained over eight years through intensive lifestyle-based weight loss in overweight adults with type 2 diabetes [30]. Current AHA/ACC guidelines further recognize GLP-1 receptor agonists (e.g., semaglutide) as evidence-based adjuncts for blood pressure management through weight reduction when lifestyle modification alone is insufficient in eligible patients [16]. 3.5 Smoking Cessation The U.S. Surgeon General’s Report (2020) confirmed that former smokers progressively approach the cardiovascular risk profile of never-smokers within 10–15 years of cessation [18]. Effective interventions combine pharmacotherapy (varenicline, bupropion, or nicotine replacement therapy) with behavioral counseling; combined approaches consistently achieve the highest long-term cessation rates [31]. Population-level tobacco control measures—including excise taxation, smoke-free workplace legislation, and mass media campaigns—remain essential complements to individual clinical interventions. 3.6 Alcohol Reduction The 2024 ISH position paper confirms that reducing alcohol intake in heavy drinkers by approximately 3.8 standard drinks per day produces SBP reductions of up to 5.5 mmHg [6]. Brief Alcohol Intervention counseling, a structured 5–15-minute consultation delivered in primary care settings, is evidence-based, cost-effective, feasible, and should be systematically integrated into hypertension prevention programs [32]. 3.7 Stress Management The 2024 ISH position paper documents that 45 minutes of daily yoga practiced over 12 weeks reduces SBP by 6.5 mmHg and DBP by 2.8 mmHg [6]. Mindfulness-Based Stress Reduction , cognitive-behavioral therapy , and progressive muscle relaxation have each demonstrated blood pressure-lowering effects in clinical trials [6,33]. While stress management techniques produce more modest blood pressure effects than dietary or exercise interventions in isolation, their positive impact on psychological well-being, self-efficacy, and motivation enhances adherence to the broader lifestyle modification program—justifying their inclusion in comprehensive prevention strategies. Multi-Component Interventions and Digital Health Delivery Multi-component lifestyle interventions that address several behavioral risk factors simultaneously consistently outperform single-factor approaches. The PREMIER clinical trial demonstrated mean SBP reductions exceeding 14 mmHg in hypertensive participants after 18 months of combined dietary modification, exercise, sodium reduction, and weight management, compared to modest changes in the advice-only control group [34]. A 2024 systematic review and meta-analysis by Bulto et al. (31 RCTs) confirmed that nurse-led multi-component lifestyle interventions reduce SBP by a mean of 4.66 mmHg (95% CI: −6.69 to −2.64) compared to usual care, with positive effects on both dietary modification and physical activity [35]. Digital health platforms are emerging as scalable, cost-efficient mechanisms for lifestyle intervention delivery. A 2025 systematic review and meta-analysis in the Journal of Human Hypertension found significant blood pressure reductions from digital interventions targeting lifestyle factors in hypertension, with the strongest evidence for programs combining dietary and physical activity components with behavioral support [36]. A 2024 EClinicalMedicine review by Boima et al. confirmed meaningful improvements in blood pressure control, lifestyle behaviors, and medication adherence from digital health interventions deployed across 18 LMICs [37], underscoring their particular potential for equitable scale-up in resource-constrained settings. Barriers to Adherence and Implementation Despite robust efficacy evidence, real-world adherence to lifestyle modification programs remains critically low. The 2025 WHO EMRO systematic review of 30 studies (2019–2024) reported a mean cumulative global adherence rate of just 27.4% among hypertensive patients: physical activity adherence was 34.3%, dietary compliance 47.7%, and sodium restriction 54.6% [8]. Individual-level barriers identified across studies included low health literacy, financial constraints, habit inertia, forgetfulness, lack of motivation and social support, and pervasive misconceptions about hypertension severity and treatability [8]. A 2023 Nigerian study confirmed that non-adherence to lifestyle recommendations was the leading predictor of poor blood pressure control in a rural teaching hospital setting, compounded by limited dietary knowledge, economic constraints, and inconsistent provider counseling [38]. This finding highlights that adherence barriers in LMICs are not merely behavioral but deeply embedded in structural and socioeconomic realities. Systemic barriers include limited primary care capacity for lifestyle counseling, short consultation times, inadequate provider training in behavioral medicine, fragmented service delivery, and the near-absence of structured lifestyle programs within most LMIC health systems. Addressing these barriers requires a socio-ecological approach targeting change at individual, interpersonal, community, health system, and policy levels simultaneously. The “5As” clinical framework (Ask, Advise, Assess, Assist, Arrange) provides a practical, evidence- based structure for integrating brief lifestyle counseling into routine clinical encounters without requiring significant additional consultation time. Discussion This scoping review synthesizes 47 sources spanning 2000–2025 to confirm that hypertension is largely preventable through targeted lifestyle modification, and that the evidence base has been substantially strengthened by recent landmark publications. The principal original contribution of this review is its dual focus: synthesizing the 2020–2025 guideline landscape—including the pivotal 2024 ESC and ISH reclassifications [6,7]—while explicitly examining the implementation gap between efficacy evidence and real-world adherence in LMICs. Prior reviews have addressed intervention efficacy or adherence barriers in isolation; this review integrates both dimensions to argue that the core challenge is no longer identifying what works, but understanding how to deliver it equitably and sustainably at scale. The magnitude of achievable blood pressure reduction through multi-component lifestyle programs is clinically and epidemiologically significant. Reductions of 5–16 mmHg SBP translate, on the basis of Lewington et al.’s meta-analysis of one million adults, to estimated reductions in stroke risk of 27% and coronary heart disease risk of 17% per 10 mmHg sustained SBP reduction [39]. At population level, a modest downward shift of even 2 mmHg in mean SBP distribution substantially reduces cardiovascular event burden. Important limitations of the existing evidence base constrain the conclusions of this review. Most high-quality clinical trials have been conducted in high-income, Western settings with relatively homogeneous participant populations, limiting direct generalizability to Sub-Saharan Africa, South Asia, and other LMICs where hypertension burden is greatest and growing fastest. Follow- up periods in most trials are relatively short (typically 6–24 months), inadequately capturing long-term adherence and sustained blood pressure trajectories. Culturally adapted dietary guidelines employing affordable, locally available equivalents of the DASH dietary pattern remain insufficiently developed and evaluated. Future research should prioritize implementation trials in LMIC settings, long-term follow-up designs, and co-designed interventions developed with communities rather than for them. The social determinants of health—including poverty, food insecurity, educational attainment, neighborhood safety, occupational hazards, and access to recreational infrastructure—profoundly shape both hypertension risk and individuals’ capacity to adopt and sustain lifestyle modifications. Behavioral interventions that do not account for structural determinants risk placing disproportionate and inequitable responsibility on individuals for health outcomes substantially shaped by circumstances beyond personal control. Effective hypertension prevention policy must therefore operate at the structural level—through food environment reform, tobacco taxation, urban design for active transport, and investment in community health infrastructure—in parallel with clinical and individual-level behavioral interventions. Conclusions This scoping review confirms that hypertension is substantially preventable through targeted, evidence-based lifestyle modification. Seven behavioral risk factors—high dietary sodium intake, physical inactivity, overweight and obesity, tobacco use, harmful alcohol consumption, chronic psychosocial stress, and sleep disruption—collectively account for a large and modifiable share of hypertension risk. Structured lifestyle interventions targeting these behaviors produce clinically meaningful blood pressure reductions, now endorsed at the highest level of clinical evidence by international guidelines. The central challenge, however, is not identifying effective interventions but delivering them equitably at scale. With global adherence averaging only 27.4%, the implementation gap is the defining barrier to hypertension prevention in the 21st century. Closing this gap requires: strengthened primary care capacity for lifestyle counseling; deployment of digital health platforms and community health workers as delivery mechanisms; policy-level food, tobacco, and built-environment interventions; and investment in culturally adapted, co-designed programs for LMIC contexts. Future research must prioritize implementation science, long-term adherence mechanisms, and structural-level interventions that create the enabling environments in which healthy behavioral choices become the easier, more accessible default. List of Abbreviations AHA/ACC: American Heart Association / American College of Cardiology; BAI: Brief Alcohol Intervention; BMI: Body Mass Index; CBT: Cognitive Behavioural Therapy; CKD: Chronic Kidney Disease; CVD: Cardiovascular Disease; DASH: Dietary Approaches to Stop Hypertension; DBP: Diastolic Blood Pressure; ESC: European Society of Cardiology; HPA: Hypothalamic-Pituitary-Adrenal; ISH: International Society of Hypertension; LMICs: Low- and Middle-Income Countries; MBSR: Mindfulness-Based Stress Reduction; MeSH: Medical Subject Headings; NCD: Non-Communicable Disease; OSA: Obstructive Sleep Apnea; PCC: Population, Concept, Context; PRISMA-ScR: Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews; RAAS: Renin-Angiotensin-Aldosterone System; RCT: Randomized Controlled Trial; SBP: Systolic Blood Pressure; WHO: World Health Organization; WHL: World Hypertension League. References 1. World Health Organization. Hypertension: key facts [Internet]. Geneva: WHO; 2023 [cited 2025 Mar 15]. Available from: https://www.who.int/news-room/fact- sheets/detail/hypertension 2. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223–49. 3. NCD Risk Factor Collaboration. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population- representative studies with 104 million participants. Lancet. 2021;398(10304):957–80. 4. Adeloye D, Owolabi EO, Ojji DB, Auta A, Dewan MT, Olanrewaju TO, et al. Prevalence, awareness, treatment, and control of hypertension in Nigeria in 1995 and 2020: a systematic analysis of current evidence. J Clin Hypertens. 2021;23(5):857–70. 5. Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75(2):285–92. 6. Charchar FJ, Prestes PR, Mills C, Ching SM, Neupane D, Marques FZ, et al. Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J Hypertens. 2024;42(1):23–49. 7. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018. 8. Alanazi R, Alzahrani AA, Alzahrani RA, Al-Dossari RA, Alanazi AM, Alzahrani MF, et al. A systematic review of adherence to lifestyle modifications by hypertensive patients. East Mediterr Health J. 2025;31(9–10):590–6. 9. He FJ, Tan M, Ma Y, MacGregor GA. Salt reduction to prevent hypertension and cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(6):632– 47. 10. Powles J, Fahimi S, Micha R, Khatibzadeh S, Shi P, Ezzati M, et al. Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open. 2013;3(12):e003733. 11. Rauber F, Da Costa Louzada ML, Steele EM, Millett C, Monteiro CA, Levy RB. Ultra- processed food consumption and chronic non-communicable diseases-related dietary nutrient profile in the UK (2008–2014). Nutrients. 2018;10(5):587. 12. Filippou CD, Tsioufis CP, Thomopoulos CG, Mihas CC, Dimitriadis KS, Sotiropoulou LI, et al. Dietary Approaches to Stop Hypertension diet and blood pressure reduction in adults with and without hypertension: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr. 2020;11(5):1150–60. 13. Huai P, Xun H, Reilly KH, Wang Y, Ma W, Xi B. Physical activity and risk of hypertension: a meta-analysis of prospective cohort studies. Hypertension. 2013;62(6):1021–6. 14. Edwards JJ, Deenmamode AHP, Griffiths M, Arnold O, Cooper NJ, Wiles JD, et al. Exercise training and resting blood pressure: a large-scale pairwise and network meta-analysis of randomised controlled trials. Br J Sports Med. 2023;57(20):1317–26. 15. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991–1006. 16. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127–248. [Note to author: please verify and update to the AHA/ACC 2025 guideline citation upon publication before submission.] 17. Kalkhoran S, Benowitz NL, Rigotti NA. Prevention and treatment of tobacco use: JACC health promotion series. J Am Coll Cardiol. 2018;72(9):1030–45. 18. U.S. Department of Health and Human Services. Smoking cessation: a report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2020. 19. Cecchini M, Filippini T, Whelton PK, Iamandii I, Di Federico S, Boriani G, et al. Alcohol intake and risk of hypertension: a systematic review and dose-response meta-analysis of nonexperimental cohort studies. Hypertension. 2024;81(8):1701–15. 20. Steptoe A, Kivimaki M. Stress and cardiovascular disease: an update on current knowledge. Annu Rev Public Health. 2013;34:337–54. 21. Gangwisch JE, Heymsfield SB, Boden-Albala B, Buijs RM, Kreier F, Pickering TG, et al. Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension. 2006;47(5):833–9. 22. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336(16):1117–24. 23. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension diet. N Engl J Med. 2001;344(1):3–10. 24. Onwuzo C, Olukorode JO, Omokore OA, Odunaike OS, Omiko R, Osaghae OW, et al. DASH diet: a review of its scientifically proven hypertension reduction and health benefits. Cureus. 2023;15(9):e44692. 25. Irmayani N, Fitranti DY, Syauqy A, Triyono EA, Murbawani EA, Ulvie YNS. Blood pressure impact of dietary practices using the DASH method: a systematic review and meta-analysis. Clin Hypertens. 2025;31:e12. 26. Aburto NJ, Ziolkovska A, Hooper L, Elliott P, Cappuccio FP, Meerpohl JJ. Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ. 2013;346:f1326. 27. Jabbarzadeh Ganjeh B, Zeraattalab-Motlagh S, Jayedi A, Daneshvar M, Gohari Z, Norouziasl R, et al. Effects of aerobic exercise on blood pressure in patients with hypertension: a systematic review and dose-response meta-analysis of randomized trials. Hypertens Res. 2024;47(2):385–98. 28. Jafari A, Vakili MA, Hasani M, Amirkhani R, Gorji HA. The effect of physical activity intervention on blood pressure in 18 low and middle-income countries: a systematic review and meta-analysis of randomized controlled trials. Clin Hypertens. 2024;30:22. 29. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42(5):878–84. 30. Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54. 31. Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2016;3:CD008286. 32. Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OS, Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta- analysis. Lancet Public Health. 2017;2(2):e108–20. 33. Shi L, Zhang D, Wang L, Zhuang J, Cook R, Chen L. Meditation and blood pressure: a meta- analysis of randomized clinical trials. J Hypertens. 2017;35(4):696–706. 34. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289(16):2083–93. 35. Bulto LN, Roseleur J, Noonan S, Pinero de Plaza MA, Champion S, Dafny HA, et al. Effectiveness of nurse-led interventions versus usual care to manage hypertension and lifestyle behaviour: a systematic review and meta-analysis. Eur J Cardiovasc Nurs. 2024;23(1):21–32. 36. Sievert K, Lawrence M, Malica A, Harris MF. A systematic review and meta-analysis of digital interventions targeting lifestyle factors in patients with hypertension. J Hum Hypertens. 2025. doi:10.1038/s41371-025-01051-3. 37. Boima V, Doku A, Agyekum F, Tuglo LS, Agyemang C. Effectiveness of digital health interventions on blood pressure control, lifestyle behaviours and adherence to medication in patients with hypertension in low-income and middle-income countries: a systematic review and meta-analysis. EClinicalMedicine. 2024;69:102432. 38. Oseni TI, Emonriken A, Ahmed SD, Dic-Ijiewere M. Determinants of blood pressure control among hypertensive patients attending a rural teaching hospital in Southern Nigeria. Niger J Clin Pract. 2023;26(3):260–6. 39. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13. 40. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–37.